BioSpace News Archive

Hutchison China MediTech Limited announces that new and updated analyses on the ongoing studies of surufatinib will be presented at the upcoming American Association for Cancer Research Virtual Annual Meeting I, taking place on April 27, 2020.

Transparency Market Research has published a new report on the anal irrigation systems market for the forecast period of 2019–2027.

Transparency Market Research has published a new report on the atherosclerosis drugs market.

Transparency Market Research has published a new report on the burn injury treatment market for the forecast period of 2019-2027. According to the report, the global burn injury treatment market was valued at ~US$ 2.6 Bn in 2018.

First COVID-19-related clinical trial to start in Germany Initial dose escalation phase to target dose range of 1µg to 100µg Clinical supply from BioNTech’s GMP-certified mRNA production facilities in Europe Four vaccine candidates to enter clinical development MAINZ, Germany and NEW YORK, April 22, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) and Pfizer Inc. (NYSE: PFE), have announced today that the German regulatory authority, the

Physician group stands up technology solution to maintain continuity of care for at-risk patients [22-April-2020] DENVER , April 22, 2020 /PRNewswire/ -- Nephrology Care Alliance (NCA), a nephrologist-led organization that seeks to empower physicians to succeed in a changing health care environment, recently formalized a collaboration with Mend, a leading tele

Akili announced that ENDEAVORTM is now available for use by children with attention deficit hyperactivity disorder and their families.

The most comprehensive suite of molecular testing in the industry includes a new whole exome sequencing (DNA) assay complementing the Company’s breakthrough whole transcriptome sequencing (RNA) performed on every patient

REGENXBIO Inc., a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, provided additional long-term data from the ongoing Phase I/IIa trial of RGX-314 for the treatment of wet age-related macular degeneration.

Quest Diagnostics Incorporated, the world’s leading provider of diagnostic information services, announced financial results for the first quarter ended March 31, 2020.